Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 21, 1999FEBS LettersOpen Access

Use of a drug‐resistant mutant of stress‐activated protein kinase 2a/p38 to validate the in vivo specificity of SB 203580

View Full Paper
Ask AI
Bookmark
Share

Authors

PEPatrick A. EyersUniversity of LiverpoolPIPaul van den IJsselAmsterdam UMC Location Vrije Universiteit AmsterdamRQRoy A. QuinlanDurham University

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Eyers et al. (1999) studied this question.

synapsesocial.com/papers/6a9073bd6bfd95d7bd4de7abhttps://doi.org/10.1016/s0014-5793(99)00552-9
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Role of p38 and JNK Mitogen-Activated Protein Kinases in the Activation of Ternary Complex Factors1997 · 464 citations
  2. 2Acquisition of Sensitivity of Stress-activated Protein Kinases to the p38 Inhibitor, SB 203580, by Alteration of One or More Amino Acids within the ATP Binding Pocket1998 · 228 citations